Claims for Patent: 7,960,106

Summary for Patent: 7,960,106

Title:	Diagnostic method and products useful therein
Abstract:	A method for simultaneous detection and identification of Bacillus anthracis, Yersinia pestis and Francisella tularensis, in a single real time PCR assay using species-specific primers and Taqman MGB probes. Also, a kit for the diagnosis of bacterial bioterrorism agents. In addition, an infection-free control plasmid to verify the result of the real time PCR analysis method.
Inventor(s):	Nikkari; Simo (Turku, FI), Skottman; Tuukka (Helsinki, FI), Skurnik; Mikael (Masala, FI)
Assignee:	The Finnish Defence Forces (Helsinki, FI)
Application Number:	11/634,154
Patent Claims:	1. A method for simultaneously detecting the presence or absence of Bacillus anthracis, Yersinia pestis and Francisella tularensis in a sample, the method comprising: obtaining DNA from the sample; performing a single real time PCR assay run using species-specific Taqman MGB probes and species-specific primers; and detecting fluorescence of the probes; wherein: the forward and reverse primers for B. anthracis have the sequences of SEQ ID NOS: 1 and 2, respectively, derived from the pagA gene and SEQ ID NOS: 4 and 5, respectively, derived from the capB gene, the forward and reverse primers for Y. pestis have the sequences of SEQ ID NOS: 7 and 8, respectively, derived from the pla gene, the forward and reverse primers for F. tularensis have the sequences of SEQ ID NOS: 10 and 11, respectively, derived from the 23 kDa gene, the concentrations of said forward primers and said reverse primers are optimized in the range of 50-900 nM under the same temperature parameters, the specific Taqman MGB probe comprises a sequence selected from the group of full-length sequences set forth in SEQ ID NOS: 3, 6, 9, and 12. 2. A method of claim 1 wherein the optimal conditions in the real time PCR assay are for B. anthracis 300 nM forward primer, 900 nM reverse primer and 250 nM of Taqman MGB probe, for Y. pestis 50 nM forward primer, 300 nM reverse primer and 250 nM of Taqman MGB probe, and for F. tularensis 300 nM forward primer, 900 nM reverse primer and 250 nM of Taqman MGB probe. 3. A method of claim 1 wherein a multiplex PCR-format is used, and the reactions are performed in a single assay tube using differently labeled Taqman MGB probes. 4. The method according to claim 1, wherein the optimal conditions in the real time PCR assay are for B. anthracis 300 nM forward primer, 900 nM reverse primer and 250 nM of Taqman MGB probe, for Y. pestis 50 nM forward primer, 300 nM reverse primer and 250 nM of Taqman MGB probe, and for F. tularensis 300 nM forward primer, 900 nM reverse primer and 250 nM of Taqman MGB probe. 5. The method according to claim 1, wherein a multiplex PCR-format is used, and the reactions are performed in a single assay tube using differently labeled Taqman MGB probes. 6. The method according to claim 2, wherein a multiplex PCR-format is used, and the reactions are performed in a single assay tube using differently labeled Taqman MGB probes. 7. The method according to claim 4, wherein a multiplex PCR-format is used, and the reactions are performed in a single assay tube using differently labeled Taqman MGB probes. 8. The method of claim 1, wherein the sample is a bacterial culture, a tissue fragment, a secretion sample, a blood sample, a clinical sample from a lumbar puncture or abscesses, obtained from a patient. 9. The method of claim 1, wherein the sample is an environmental sample, a paper sample, or an air sample collected from the site to be examined.

Details for Patent 7,960,106

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821	11/12/1998		2025-12-08